Product
CUTAQUIG
1 clinical trial
1 indication
Indication
Primary Immune Deficiency DisorderClinical trial
Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2022-01-03